About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

JC Virus Reactivation in Multiple Sclerosis | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02004444

JC Virus Reactivation in Multiple Sclerosis

JC virus is a benign virus which infects approximately up to 90% of the normal adult population. However, it may be reactivated in people who have a decreased immune function as in HIV infection, canc...

Lead sponsor: Beth Israel Deaconess Medical Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Beth Israel Deaconess Medical Center

Collaborators

National Multiple Sclerosis Society
Biogen

Subjects selected for participation in this study have been diagnosed with Multiple Sclerosis (MS). Of the MS patients enrolled in the study, some have been treated with natalizumab or a different medication for MS, and others have not been treated at all. All MS patients enrolled have their blood tested for the presence of the JC virus. Those testing negative for the JC virus do not continue in the study. Those testing positive for the JC virus continue participating in the study, and provide a urine sample, blood sample, lumbar puncture, and a neurological exam. Approximately 65 people will take part in this study at Beth Israel Deaconess Medical Center.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Clinical diagnosis of Multiple Sclerosis, relapsing remitting

Exclusion Criteria

•JCV sero-negative

Related studies

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

NCT06433752 · Relapsing Multiple Sclerosis, Multiple Sclerosis

RECRUITINGPhase 3

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

NCT06846281 · Relapsing Multiple Sclerosis

Nomad P-KAFO Study

NCT05644522 · Cerebrovascular Accident, Post-polio Syndrome, and more

RECRUITINGPhase 2

Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

NCT07497399 · Multiple Sclerosis

RECRUITINGPhase 3

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

NCT06847724 · Relapsing Multiple Sclerosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 29, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment50

Start dateOct 2010

Last updatedJan 29, 2016

Condition

Progressive Multifocal Leukoencephalopathy Multiple Sclerosis

Locations shown

Beth Israel Deaconess Medical Center

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 29, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions